We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
EZETIMIBE MSD, ZIENT (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
EZETIMIBE MSD, ZIENT
Date registered
Evaluation commenced
Decision date
Approval time
44 working days (255)
Active ingredients
ezetimibe
Registration type
EOI
Indication
Generic medicine
EZETIMIBE MSD, ZIENT is now also indicated for:
- Prevention of Cardiovascular Disease
EZETIMIBE MSD, ZIENT is indicated for administration in combination with the maximum tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) in need of additional lowering of LDL-C in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy.